Abiopharma

Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome

Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome

Legend Biotech Reports Second Quarter 2025 Results and Recent Highlights

Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update

New Form 8-K - Energous Corp Filed: 2025-08-11 AccNo: 0001104659-25-075898 Size: 280 KB Item 3.03: Material Modifications to Rights of Security Holders Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

New Form 6-K - KAMADA LTD Filed: 2025-08-11 AccNo: 0001213900-25-073908 Size: 27 KB

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results

New Form 8-K - Stoke Therapeutics, Inc. Filed: 2025-08-11 AccNo: 0001193125-25-177433 Size: 174 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025

Biohaven Reports Second Quarter 2025 Financial Results and Recent Business Developments

New Form 6-K - GSK plc Filed: 2025-08-11 AccNo: 0001654954-25-009310 Size: 5 MB

New Form 8-K - OWENS & MINOR INC/VA/ Filed: 2025-08-11 AccNo: 0001193125-25-177426 Size: 856 KB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

New Form SCHEDULE 13G - ADMA BIOLOGICS, INC. Filed: 2025-08-11 AccNo: 0000093751-25-000431 Size: 8 KB

New Form SCHEDULE 13G - 908 Devices Inc. Filed: 2025-08-11 AccNo: 0000093751-25-000429 Size: 9 KB